Divalproex Sodium Treatment of Women With Borderline Personality Disorder and Bipolar II Disorder: A Double-Blind Placebo-Controlled Pilot Study
The DOI matches its Crossref record.
Abstract
BACKGROUND: The intent of this study was to compare the efficacy and safety of divalproex sodium and placebo in the treatment of women with borderline personality disorder and comorbid bipolar II disorder. METHOD: We conducted a placebo-controlled double-blind study of divalproex sodium in 30 female subjects aged 18 to 40 years who met Revised Diagnostic Interview for Borderlines and DSM-IV criteria for borderline personality disorder and DSM-IV criteria for bipolar II disorder. Subjects were randomly assigned to divalproex sodium or placebo in a 2:1 manner. Treatment duration was 6 months. Primary outcome measures were changes on the interpersonal sensitivity, anger/hostility, and depression scales of the Symptom Checklist 90 (SCL-90) as well as the total score of the modified Overt Aggression Scale (MOAS). RESULTS: Twenty subjects were randomly assigned to divalproex sodium; 10 subjects to placebo. Using a last-observation-carried-forward paradigm and controlling for baseline severity, divalproex sodium proved to be superior to placebo in diminishing interpersonal sensitivity and anger/hostility as measured by the SCL-90 as well as overall aggression as measured by the MOAS. Adverse effects were infrequent. CONCLUSION: The results of this study suggest that divalproex sodium may be a safe and effective agent in the treatment of women with criteria-defined borderline personality disorder and comorbid bipolar II disorder, significantly decreasing their irritability and anger, the tempestuousness of their relationships, and their impulsive aggressiveness.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The 2012 CANMAT Task Force recommendations for comorbid personality disorder concluded that divalproex (level 3)466 and lamotrigine (level 4)759 may provide some symptomatic relief for comorbid borderline personality disorder.”
Citations
Cites
Still being checked.
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Borderline personality disorder
Lieb, K., Zanarini, M. C., Schmahl, C., Linehan, M. M., & Bohus, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16770-6 · Cited by 1,369
Self-citationGoodwin, G., Haddad, P., Ferrier, I., Aronson, J., Barnes, T., Cipriani, A., Coghill, D., Fazel, S., Geddes, Jr., Grunze, H., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116636545 · Cited by 1,309
Borderline personality disorder
Leichsenring, F., Leibing, E., Kruse, J., New, A. S., & Leweke, F. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61422-5 · Cited by 895
What Is a “Mood Stabilizer”? An Evidence-Based Response
Bauer, M. S., & Mitchner, L. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.1.3 · Cited by 862
Metadata
- Authors
- Frankenburg, F. R., & Zanarini, M. C.
- Affiliations
- Harvard University (US)
- ORCID
- Zanarini, Mary C.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2002-05-15
- Volume
- 63
- Issue
- 5
- Pages
- 442-446
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W1974269333
- Cited by
- 221
- References
- 0
- Citations by year
- 2026: 1 · 2024: 6 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 4 · 2019: 7 · 2018: 2 · 2017: 11 · 2016: 4 · 2015: 4 · 2014: 11 · 2013: 15 · 2012: 11
- FWCI
- 20.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Personality Disorders and Psychopathology
- Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- divalproex sodium, valproic acid, borderline personality disorder, bipolar II disorder, comorbidities, women, aggression, anger, irritability, interpersonal sensitivity, treatment efficacy, drug safety
- MeSH terms
- Adult, Aggression, Anger, Anticonvulsants, Bipolar Disorder, Borderline Personality Disorder, Depressive Disorder, Double-Blind Method, Female, Hostility, Humans, Personality Inventory, Pilot Projects, Placebos, Psychiatric Status Rating Scales, Sex Factors, Valproic Acid, Comorbidity, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Divalproex Sodium Treatment of Women With Borderline Personality Disorder and Bipolar II Disorder: A Double-Blind Placebo-Controlled Pilot Study. https://app.cochat.ai/papers/10.4088/jcp.v63n0511
- The paper
- Frankenburg, F. R., & Zanarini, M. C. (2002). Divalproex Sodium Treatment of Women With Borderline Personality Disorder and Bipolar II Disorder: A Double-Blind Placebo-Controlled Pilot Study. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v63n0511
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.